Clinical Trials Logo

Clinical Trial Summary

This is a multicenter, double blind, active-controlled, randomized, parallel group study to demonstrate the anti-viral activity and safety of Baracle Tab. and Baraclude Tab. for patients with HBeAg Chronic Hepatitis B. The subject will receive two tablets daily for 48 days.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT01913431
Study type Interventional
Source Dong-A ST Co., Ltd.
Contact
Status Completed
Phase Phase 4
Start date September 12, 2013
Completion date November 6, 2015

See also
  Status Clinical Trial Phase
Completed NCT01940471 - Study to Compare Tenofovir Alafenamide (TAF) Versus Tenofovir Disoproxil Fumarate (TDF) in Participants With Chronic Hepatitis B Infection Who Are Positive for Hepatitis B e Antigen Phase 3